Does the Glucagon-like Peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol intake in patients with Alcohol Use Disorder and comorbid obesity?

Change in alcohol consumption, defined as the change in percentage of heavy drinking days during a period of 30 consecutive days* , after 26 weeks of treatment adjusted for baseline (percentage points (pp)). The 30-day period will be the 30 consecutive days with the biggest alcohol intake (most heavy drinking days and the largest amount of total alcohol intake) out of the 40 days prior to the evaluation, measured by the TLFB method